이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Lantheus Holdings 미래 성장

Future 기준 확인 2/6

Lantheus Holdings은 연간 수입과 매출이 각각 11%와 13% 증가할 것으로 예상되고 EPS는 연간 8.7%만큼 증가할 것으로 예상됩니다.

주요 정보

11.0%

수익 성장률

8.7%

EPS 성장률

Medical Equipment 수익 성장	16.7%
매출 성장률	12.8%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	15 Jul 2024

최근 미래 성장 업데이트

Recent updates

Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt

Jun 24

Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus

May 23

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

May 10

Lantheus Holdings: Powerful First Quarter

May 05

Investors Should Be Encouraged By Lantheus Holdings' (NASDAQ:LNTH) Returns On Capital

Apr 12

Lantheus Holdings: Undervalued With A Good Outlook

Feb 28

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Feb 24

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively

May 29

Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly

Apr 16

Capital Allocation Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Ideal

Feb 27

An Intrinsic Calculation For Lantheus Holdings, Inc. (NASDAQ:LNTH) Suggests It's 48% Undervalued

Jan 16

Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt

Dec 24

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively

Oct 31

Does This Valuation Of Lantheus Holdings, Inc. (NASDAQ:LNTH) Imply Investors Are Overpaying?

Oct 04

Looking In On Lantheus Holdings

Sep 14

Lantheus Holdings a buy at B Riley on growth spurred by approval of imaging agent

Aug 25

Lantheus Non-GAAP EPS of $0.89 beats by $0.19, revenue of $223.72M beats by $19.21M

Aug 04

Lantheus Holdings (NASDAQ:LNTH) May Have Issues Allocating Its Capital

Jul 22

Lantheus Holdings Rules The Medical Diagnostics Business World

Jul 06

We Think Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt With Ease

Jun 25

수익 및 매출 성장 예측

NasdaqGM:LNTH - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	1,881	599	642	654	8
12/31/2025	1,615	417	684	341	11
12/31/2024	1,515	458	777	542	11
3/31/2024	1,366	461	268	324	N/A
12/31/2023	1,296	327	213	305	N/A
9/30/2023	1,206	104	-46	298	N/A
6/30/2023	1,125	33	-61	275	N/A
3/31/2023	1,027	-18	60	380	N/A
12/31/2022	935	28	3	282	N/A
9/30/2022	801	107	172	190	N/A
6/30/2022	664	32	87	101	N/A
3/31/2022	542	-37	42	54	N/A
12/31/2021	425	-71	42	54	N/A
9/30/2021	390	-34	29	41	N/A
6/30/2021	376	-27	32	45	N/A
3/31/2021	341	-8	5	17	N/A
12/31/2020	339	-13	4	16	N/A
9/30/2020	335	0	25	38	N/A
6/30/2020	332	12	43	56	N/A
3/31/2020	352	25	65	79	N/A
12/31/2019	347	32	58	80	N/A
9/30/2019	344	35	51	75	N/A
6/30/2019	347	39	47	73	N/A
3/31/2019	347	42	44	72	N/A
12/31/2018	343	41	41	61	N/A
9/30/2018	338	124	38	57	N/A
6/30/2018	329	124	31	48	N/A
3/31/2018	333	127	34	49	N/A
12/31/2017	331	123	N/A	55	N/A
9/30/2017	324	31	N/A	54	N/A
6/30/2017	318	27	N/A	54	N/A
3/31/2017	307	21	N/A	51	N/A
12/31/2016	302	27	N/A	50	N/A
9/30/2016	299	26	N/A	49	N/A
6/30/2016	300	27	N/A	39	N/A
3/31/2016	295	-5	N/A	10	N/A
12/31/2015	293	-15	N/A	22	N/A
9/30/2015	299	-18	N/A	5	N/A
6/30/2015	301	-25	N/A	20	N/A
3/31/2015	303	-2	N/A	27	N/A
12/31/2014	302	-4	N/A	12	N/A
9/30/2014	296	-16	N/A	12	N/A
6/30/2014	291	-30	N/A	-5	N/A
3/31/2014	286	-43	N/A	-15	N/A
12/31/2013	284	-62	N/A	-16	N/A
9/30/2013	284	-59	N/A	-34	N/A

애널리스트 미래 성장 예측

수입 대 저축률: LNTH 의 연간 예상 수익 증가율( 11% )이 saving rate( 2.4% 보다 높습니다. ).

수익 vs 시장: LNTH 의 연간 수익( 11% ) US 시장( 14.9% 보다 느리게 성장할 것으로 예상됩니다. 14.9% 연간).

고성장 수익: LNTH 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: LNTH 의 수익(연간 13% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: LNTH 의 수익(연간 13% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: LNTH 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

Lantheus Holdings 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates increase by 27%

Price target increased by 8.3% to US$106

Lantheus Holdings, Inc. Revises Revenue Guidance for the Full Fiscal Year 202

Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Lantheus Holdings, Inc. Provides Revenue Guidance for Its Fiscal Year Ended December 31, 2023

Price target decreased by 7.7% to US$108

Recent updates

Lantheus Holdings, Inc. Appoints Jamie Spaeth as Chief People Officer

Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt

Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus

Lantheus Holdings, Inc. Announces Management Appointments, Effective May 28, 2024

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Consensus EPS estimates increase by 27%

Lantheus Holdings: Powerful First Quarter

Price target increased by 8.3% to US$106

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lantheus Holdings, Inc. Revises Revenue Guidance for the Full Fiscal Year 202

Investors Should Be Encouraged By Lantheus Holdings' (NASDAQ:LNTH) Returns On Capital

CFO & Treasurer notifies of intention to sell stock

Lantheus Holdings, Inc., Annual General Meeting, Apr 25, 2024

Chairman of the Board notifies of intention to sell stock

Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients

Investor sentiment improves as stock rises 15%

Lantheus Holdings: Undervalued With A Good Outlook

Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce

Full year 2023 earnings: EPS exceeds analyst expectations

Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly

Lantheus Holdings, Inc. Announces CEO Changes, Effective March 1, 2024

Lantheus Holdings, Inc. Announces Acceptance of its First-to-File ANDA for Generic Lutathera (Lutetium Lu 177 Dotatate)

Now 25% undervalued after recent price drop

Lantheus Holdings, Inc. Provides Revenue Guidance for Its Fiscal Year Ended December 31, 2023

Market Participants Recognise Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Earnings

Investor sentiment deteriorates as stock falls 22%

Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer

Price target decreased by 7.7% to US$108

Now 31% undervalued after recent price drop

CFO & Treasurer notifies of intention to sell stock

Return Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Appealing

A Look At The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH)

CEO & Director notifies of intention to sell stock

Is Lantheus Holdings (NASDAQ:LNTH) Using Too Much Debt?

New major risk - Earnings quality

New major risk - Revenue and earnings growth

Lantheus Holdings, Inc. Updates Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Returns At Lantheus Holdings (NASDAQ:LNTH) Appear To Be Weighed Down

Lantheus Holdings, Inc. Elevates Robert J. Marshall, Jr. as Treasurer

CEO & Director notifies of intention to sell stock

Calculating The Fair Value Of Lantheus Holdings, Inc. (NASDAQ:LNTH)

New minor risk - Earnings quality

Lantheus Holdings, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does Lantheus Holdings (NASDAQ:LNTH) Have A Healthy Balance Sheet?

Ratio Therapeutics Inc. In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for Pet Imaging

Insufficient new directors

Lantheus Holdings (NASDAQ:LNTH) Might Be Having Difficulty Using Its Capital Effectively

Chief Administrative Officer notifies of intention to sell stock

Price target increased by 7.4% to US$120

Lantheus Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Business Officer notifies of intention to sell stock

Here's Why Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt Responsibly

CEO & Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Capital Allocation Trends At Lantheus Holdings (NASDAQ:LNTH) Aren't Ideal

Full year 2022 earnings released: EPS: US$0.41 (vs US$1.06 loss in FY 2021)

Investor sentiment improves as stock rises 17%

Lantheus Holdings, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Lantheus Holdings, Inc. Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels

Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium

Lantheus Holdings, Inc. (NasdaqGM:LNTH) acquired Cerveau Technologies, Inc.

An Intrinsic Calculation For Lantheus Holdings, Inc. (NASDAQ:LNTH) Suggests It's 48% Undervalued

Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt

Lantheus Holdings, Inc. Appoints Amanda Morgan as Senior Vice President, Commercial